NICE Endorses Dupilumab for Eosinophilic COPD T...

By HEOR Staff Writer

January 26, 2026

NICE Backs Dupilumab Eosinophilic COPD Option Dupilumab eosinophilic COPD treatment gains momentum as the National Institute for Health and Care Excellence (NICE) final draft guidance re...
NICE Endorses Talazoparib Enzalutamide for Prostate Cancer Treatment
Trump Economic Revival: Key Policies and Impacts from Davos 2026
Long-Term Benefits of Composite Treatment Targets in Type 2 Diabetes Management
EU Medicine Authorizations 2025: A Milestone for Innovation and Accessibility
EU Launches Joint Scientific Consultations to Enhance Health Technology Asses...
Johnson & Johnson’s Medicine Access Agreement: Paving the Way for ...
NHS Cost-Effectiveness Thresholds Boost Drug Approvals and Innovation
Driving Economic Transformation through Brain Health Investment in Africa
NICE Endorses Natalizumab RRMS Treatment Expansion for Refractory Cases
Novartis Drug Pricing Agreement
INFARMED Leadership Appointments: A New Era in Health Regulation and Expertise
Preparing for the EU Health Technology Assessment: Key Insights from the Upco...